Advertisement
Screener

Organon & Co. (OGN) Analyst Insights

RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$13.85(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$13.85High(m)Average(m)Low(m)2025-11-062026-11-06
DateStockAnalystFirmPrice When RatedPrice TargetUpside / DownsideRatingPerformance
2026-02-23OGN
Organon & Co.
Glen SantangeloBarclays$8.10$8.00-1.23%Underweight
2025-12-08OGN
Organon & Co.
Glen SantangeloBarclays$7.14$7.50+5.04%Underweight
2025-03-25OGN
Organon & Co.
Glen SantangeloBarclays$15.33Overweight
2025-02-13OGN
Organon & Co.
Glen SantangeloBarclays$14.70$24.00+63.27%Overweight
2024-02-15OGN
Organon & Co.
Glen SantangeloBarclays$18.62$26.00+39.63%Overweight
2023-11-06OGN
Organon & Co.
Glen SantangeloBarclays$12.56$25.00+99.04%Overweight

Similar stocks

Stock NameCountryMarket CapPE Ratio
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53